Any current/future new fundraising through debt or equity?

Promoters have taken an unsecured interest-free loan of Rs. 60 crores to the company, which is part of the total loan of Rs. 218 crores as of March 31, 2017. External borrowings have reduced from Rs. 185 crores to Rs. 158 crores. Management is not currently focused on raising new equity; recent shares pledged have been sold, and no further share sales are planned. There is an expectation to sanction new working capital loans from banks now that the demerger is complete. Promoters have expressed commitment to increase their shareholding but have not detailed the means. Long-term loans are being

Any current/future capex/capital investment/strategic investment?

The company is focusing on contract manufacturing (job working) by utilizing external facilities to avoid heavy CAPEX investments. They have already engaged about five different external facilities for job working to enhance flexibility and reduce capital expenditure. Future growth will be supported by this model rather than in-house expansion, thus limiting CAPEX needs. Long-term loans have increased to fund some CAPEX, but the company is actively repaying these loans quarterly. No explicit mention of large new CAPEX or strategic investments, with emphasis on improved working capital manageme

Future growth expectations in sales/revenue/volumes?

Company is targeting a modest growth rate of 15% to 17% in the current year (FY18). Expect continued strong growth momentum across all business segments. Specialty and higher-margin products, including advanced intermediates, are key focus areas driving growth. New product lines catering to FMCG, perfumes, fragrances, food & beverages, and nutrients expected to significantly contribute. FMCG-related products revenue expected to grow from 10-12% last year to about 25% this year, potentially doubling. Export contribution is increasing and expected to continue growing. Improved working capital cy

Future growth expectations in earnings/operating earnings/profits/EPS?

Omkar Specialty Chemicals targets a modest revenue growth of 15% to 17% in the current year (FY18). Margins are expected to be maintained, with management being "very, very fairly confident" of holding them despite pricing pressures. Focus on higher margin specialty products and innovative product lines (perfumes, fragrances, FMCG chemicals) is expected to drive growth and profitability. Working capital improvements and shift towards contract manufacturing/job working will enhance operational efficiency and reduce capital expenditure, positively impacting profits. EBITDA margin improve

Omkar Speciality ChemicalsQ4 FY17Chemicals & Petrochemicals

Omkar Speciality Chemicals Q4 FY17 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹3.41Market Cap: ₹7 CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Company is targeting a modest growth rate of 15% to 17% in the current year (FY18).
Expect continued strong growth momentum across all business segments.
Specialty and higher-margin products, including advanced intermediates, are key focus areas driving growth.
New product lines catering to FMCG, perfumes, fragrances, food & beverages, and nutrients expected to significantly contribute.
FMCG-related products revenue expected to grow from 10-12% last year to about 25% this year, potentially doubling.
Export contribution is increasing and expected to continue growing.
Improved working capital cycle and operational efficiencies support smoother growth.
Expansion into contract manufacturing/job working model to enable growth without heavy CAPEX.

Margin guidance

Category 3

Omkar Specialty Chemicals targets a modest revenue growth of 15% to 17% in the current year (FY18).
Margins are expected to be maintained, with management being "very, very fairly confident" of holding them despite pricing pressures.
Focus on higher margin specialty products and innovative product lines (perfumes, fragrances, FMCG chemicals) is expected to drive growth and profitability.
Working capital improvements and shift towards contract manufacturing/job working will enhance operational efficiency and reduce capital expenditure, positively impacting profits.
EBITDA margin improved to 16.6% in FY17 and expected to sustain or improve with higher operating efficiencies.
Expansion in FMCG division expected to grow from 10-12% of topline last year to about 25% this year, indicating diversification in revenue sources.
Management emphasizes continuing product and customer selectivity to sustain growth and profit margins.

See what Omkar Speciality Chemicals management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

Promoters have taken an unsecured interest-free loan of Rs. 60 crores to the company, which is part of the total loan of Rs. 218 crores as of March 31, 2017.
External borrowings have reduced from Rs. 185 crores to Rs. 158 crores.
Management is not currently focused on raising new equity; recent shares pledged have been sold, and no further share sales are planned.
There is an expectation to sanction new working capital loans from banks now that the demerger is complete.
Promoters have expressed commitment to increase their shareholding but have not detailed the means.
Long-term loans are being repaid quarterly, with plans to reduce them by Rs. 10-15 crores over time.
No mention of immediate large-scale future fundraising via debt or equity; focus is on managing existing loans and internal resources.

Order book

The provided transcript from Omkar Specialty Chemicals Limited’s May 24, 2017 call does not explicitly mention the current or expected order book or pending orders. However, insights related to growth expectations and business trends include: - The company is targeting growth of about 15% to 17% for the current year. - They are focusing on specialty and higher-end intermediates, which are expected to drive growth. - Expansion in FMCG-related products is expected to increase from about 10-12% of topline last year to approximately 25%. - Capacity utilization at Lasa (a subsidiary or related entity) is around 75%. - Working capital improvements and selective customer credit terms aim to support smoother order fulfillment and growth. For detailed order book or pending orders status, the document does not provide explicit figures or projections.

See what Omkar Speciality Chemicals management said on order book — free account, 30 seconds.

Capex plans

Yes

The company is focusing on contract manufacturing (job working) by utilizing external facilities to avoid heavy CAPEX investments.
They have already engaged about five different external facilities for job working to enhance flexibility and reduce capital expenditure.
Future growth will be supported by this model rather than in-house expansion, thus limiting CAPEX needs.
Long-term loans have increased to fund some CAPEX, but the company is actively repaying these loans quarterly.
No explicit mention of large new CAPEX or strategic investments, with emphasis on improved working capital management and efficient asset utilization.

Track Omkar Speciality Chemicals — get its next earnings analysis in your feed

How does Omkar Speciality Chemicals rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisOmkar Speciality Chemicals

Rev 3Mar 3

See where Omkar Speciality Chemicals sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Omkar Speciality Chemicals rank in Chemicals & Petrochemicals?

Compare Omkar Speciality Chemicals against every Chemicals & Petrochemicals company (Q4 FY17) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Omkar Speciality Chemicals's management said in earlier quarters

Earlier calls (3)

Others in Chemicals & Petrochemicals this season

Fineotex Chem (Q2 FY27)
Quarterly Total Income from Operations: ₹391.41 crore for Q2 FY 2026–27, up 169.14% year-on-year from ₹145.43 crore. Key results statement takeaways from Fineot
Agarwal Industrial Corporation (Q2 FY27)
Revenue from operations for the quarter ended 30.09.2026 is ₹20,857.66 Lakhs (Consolidated) and ₹20,595.73 Lakhs (Standalone). Key results statement takeaways f
Stallion India (Q2 FY27)
Revenue from operations for the quarter ended September 30, 2026: ₹13,603.15 lakhs . Key results statement takeaways from Stallion India Fluorochemicals Ltd's Q
Deepak Fertilisers & Petrochemicals Corp (Q2 FY27)
Q2 FY27 Operating Revenue: ₹3,334 Cr, up 11% YoY (Page 29 & 31) . Key investor presentation takeaways from Deepak Fertilisers & Petrochemicals Corp Ltd's Q2 FY2

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Omkar Speciality Chemicals Q4 FY17 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Omkar Speciality Chemicals rank in Chemicals & Petrochemicals?

Continue your research

What Omkar Speciality Chemicals's management said in earlier quarters

Others in Chemicals & Petrochemicals this season